Tonix Pharmaceuticals stock halted ahead of FDA approval news
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a $2.48 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 617,875 shares of Class A Common Stock on August 11, 2025, for approximately $3.26 million. The sales were executed at $5.28 per share, with the stock currently trading near its Fair Value according to InvestingPro analysis.
According to a Form 4 filing with the Securities and Exchange Commission, the transactions were executed under a Rule 10b5-1 trading plan adopted by Gibson on May 12, 2025. Specifically, Gibson sold 500,300 shares directly and 17,875 shares held by the Gibson Family Trust, where Gibson serves as Trustee. An additional 100,000 shares were sold indirectly through LAHWRAN-3 LLC, where Gibson is a member and manager. InvestingPro data shows the company holds more cash than debt on its balance sheet, though it has experienced a significant -46% decline over the past six months.
On the same day, Gibson also converted 423,666 shares of Class B Common Stock into Class A Common Stock. Additionally, 100,000 Class B shares held by LAHWRAN-3 LLC and 17,875 shares held by the Gibson Family Trust were converted into Class A Common Stock. These conversions were done at a price of $0. Furthermore, a gift of 10,000 shares was transacted at $0. For deeper insights into RXRX’s financial health and additional ProTips, access the comprehensive research report available on InvestingPro.
In other recent news, Recursion Pharmaceuticals reported its second-quarter 2025 earnings, revealing a mixed financial performance. The company achieved revenue of $19.22 million, surpassing analyst forecasts of $15.37 million by a notable 25.05%. However, its earnings per share (EPS) came in at -$0.41, missing the anticipated -$0.35, which resulted in a 17.14% negative surprise. Despite the shortfall in EPS, the revenue beat indicates strong sales performance. These recent developments reflect a complex financial picture for Recursion Pharmaceuticals. Investors appeared optimistic about the revenue results. Analyst responses to these earnings are yet to be detailed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.